-
Personalized Vaccines in Cancer Treatment: The Future of Immunotherapy(Post)
What Are Personalized Cancer Vaccines? Personalized cancer vaccines are a cutting-edge approach in cancer treatment that are designed to activate a patient's immune sy
Transformation Protocol – Sample Transformation Protocols(Post)Introduction Transformation of bacteria with plasmids is not only of note for bacterial studies but also can be used for gene expression studies in mammalian cells. Most plasmids are of bact
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
Understanding Antibody Staining for Antigen Detection in Flow Cytometry(Post)Flow cytometry stands as a pivotal technique in the realms of molecular biology and immunology, enabling the analysis of physical and chemical characteristics of cells or particles as they flow in
CD27 Activation: Strengthening the Immune Army Against Cancer(Post)Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa
Amino Acid and Protein Assays(Page) Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Understanding activating PIK3CA mutations in human disease(Post)Ralitsa R. Madsen – University of Cambridge Metabolic Research Laboratories Each one of us is the result of an extraordinary developmental proces
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Heterogeneity of Type 1 diabetes in children(Post)Ahmad Gazali PhD candidate, University of Eastern Finland Type 1 diabetes (T1D) is an autoimmune disease where the pancreatic β cells that produce insulin, a key hormone involved in t
Interactive Pathway Diagrams(Page) Immuno Oncology: If cancer was a pathogen, would a vaccine be able to destroy it?(Post)Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the
CD31: A Comprehensive Look at an Essential Biomarker(Post)What is CD31? CD31, also known as PECAM-1, was originally described as a cell surface antigen present on platelets and megakaryocytes. CD31 is
CD11b: Macrophages and Microglia Marker(Post)The immune system plays a critical role in defending the body against pathogens and maintaining tissue homeostasis. Within the intricate network of immune cells, CD11b, also known as integ
Immuno-Biomaterial Development | Assay Genie(Post)Background I am a 3rd year PhD student in Trinity College Dublin and my project is very much an interdisciplinary one. I’m very lucky to get to work between two great labs, Dr. Aisling Dunn
Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Flow Cytometry Protocol | 10 Hints & Tips(Post)Lab Methods · Flow CytometryFlow Cytometry Protocol: Two Worked Protocols, Controls and 10 Practical TipsFlow cytometry measures individual cells in a fluid stream at hundreds per second, reporting si
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C